cAMP signaling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
At the same time, the Central Intelligence Agency (CIA) was accused of facilitating the drug trade in Mexico and elsewhere to fund anticommunist guerilla forces in Central and South America. A number of former DEA agents, CIA agents, Mexican police officers, and historians contend that the CIA was complicit in the murder of DEA agent Kiki Camarena, who discovered and attempted to reveal the CIA's role in the drug trade. Between 2013 and 2015, the Mexican newspaper Proceso, journalist Jesús Esquivel, journalists Charles Bowden and Molly Malloy, and historians Russell and Silvia Bartley published investigative reports and books making the same allegation. They wrote that Camarena, like Mexican journalist Manuel Buendía, discovered that the CIA helped organize drug trafficking from Mexico into the United States to fund the anti-communist Contras in Nicaragua as a part of the Cold War. Historian Wil Pansters explained that US victory in the Cold War was more important to the CIA than the DEA's war on drugs:Since the overriding concern of the CIA was the anti-Sandinista project, it trumped the DEA's task of combating drug trafficking, and covertly incorporated (or pressured) parts of the Mexican state into subservience. Buendía had found out about the CIA-contra-drugs-DFS connection, which seriously questioned Mexican sovereignty, while Camarena learned that the CIA had infiltrated the DEA and sabotaged its work so as to interfere with the clandestine contra-DFS-traffickers network. They knew too much and were eliminated on the orders of the U.S. with Mexican complicity.
== Awards and honors == Strobel has received Beckman, Searle and Basil O'Connor career awards. He received the Dylan Hixon Prize for Teaching Excellence in the Natural Sciences. He also received the Yale Graduate Mentoring Award in the Sciences. He received the Yale Science and Engineering Association Award for Meritorious Service to Yale University.
=== Adhesion to dental metal === Tensile bond strengths to titanium plates treated with 3 experimental primers consisting of MDP in 3 concentrations were tested. The data obtained strongly suggest that MDP is effective to improve the adhesive performance of resin to titanium.
Sources: en.wikipedia.org
Large language models (LLMs) are trained on tokenized text from large corpora and are capable of natural language processing, machine translation, and natural language generation. LLMs can be used as foundation models for a variety of downstream tasks. They can also be trained on source code to generate programs from prompts. Many applications combine large language models with external knowledge sources using retrieval-augmented generation (RAG), a technique in which relevant documents are retrieved at inference time and incorporated into the model's response. Generative AI has been integrated into content management and website publishing platforms, where large language models are used to generate text, assist with page composition, and automate website creation from natural language prompts. WordPress.com is one example of this application, incorporating generative AI into its website authoring workflow.
In February 2018, The Marshall Project published an investigation reporting that the new label allowed Johnson & Johnson to market Invega Sustenna as a way to keep people out of prison or jail. John Snook, executive director of the Treatment Advocacy Center, described the "stay-out-of-jail" marketing approach as a "depressing commentary" on the state of mental health treatment. Critics noted that the PRIDE study did not compare Invega Sustenna with other long-acting injectable antipsychotics, only with daily oral antipsychotics, and that the reduced rate of incarceration was likely due to improved drug adherence rather than a unique property of paliperidone palmitate. A 2022 review of internal pharmaceutical industry documents, published in the Journal of Correctional Health Care, identified Janssen as one of at least two companies that directly marketed antipsychotics to jails and prisons to increase sales. The review found that marketing strategies included targeted promotions, indirect "educational" advertising, and efforts to influence state formulary advisory boards. Concerns have also been raised about industry influence on the evidence base for long‑acting injectable (LAI) antipsychotics. In a 2024 paper in Accountability in Research, Lisa Cosgrove and colleagues presented a case analysis arguing that systematic reviews comparing LAIs to oral antipsychotics can be "shaped by commercial interests" and that financial conflicts of interest among review authors may "undermine patient‑centered models of recovery and care."
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
Sources: en.wikipedia.org
Animal models have shown that at the enterocyte cell wall, β-carotene is taken up by the membrane transporter protein scavenger receptor class B, type 1 (SCARB1). Absorbed β-carotene is converted to retinal and then retinol. The first step of the conversion process consists of one molecule of β-carotene cleaved by the enzyme β-carotene-15, 15'-monooxygenase, which in humans and other mammalian species is encoded by the BCM01 gene, into two molecules of retinal. When plasma retinol is in the normal range, gene expression for SCARB1 and BC01 are suppressed, creating a feedback loop that suppresses β-carotene absorption and conversion. Absorption suppression is not complete, as receptor 36 is not downregulated.
== Clinical trials == Innovation Pharmaceuticals advanced brilacidin through early stage human clinical trials to a completed Phase 2a proof-of-concept clinical trial. Since acquisition, brilacidin was entered into a Phase 2b clinical trial. Brilacidin was granted the Qualified Infectious Disease Product (QIDP) designation by the FDA under the Generating Antibiotic Incentives Now Act of 2011 (GAIN Act).
{\displaystyle p_{u}={\begin{cases}{\dfrac {f_{u}}{\sum _{i=1}^{20}f_{i}\,+\,w\sum _{k=1}^{\lambda }\tau _{k}}},&(1\leq u\leq 20)\\[10pt]{\dfrac {w\tau _{u-20}}{\sum _{i=1}^{20}f_{i}\,+\,w\sum _{k=1}^{\lambda }\tau _{k}}},&(20+1\leq u\leq 20+\lambda )\end{cases}}\qquad {\text{(4)}}}
Negative ions are formed by resonance capture of a near-thermal energy electron, dissociative capture of a low energy electron and via ion-molecular interactions such as proton transfer, charge transfer and hydride transfer. Compared to the other methods involving negative ion techniques, NCI is quite advantageous, as the reactivity of anions can be monitored in the absence of a solvent. Electron affinities and energies of low-lying valencies can be determined by this technique as well.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.